Metabolic health and liver disease in Polish twins

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a five-year observational cohort using a trial-within-cohort design to document new cases and progression of MASLD, liver fibrosis, cirrhosis, and other metabolic syndrome complications among Polish twins aged 15–44. Twin pairs with a living co-twin who provide informed consent will contribute medical and family histories and undergo periodic clinical exams, laboratory testing, and liver imaging to track incident disease and progression. The protocol excludes participants with pre-existing advanced liver disease, specific genetic or autoimmune liver disorders, high chronic alcohol intake, or inability to provide family medical history. The study will also analyze whether prior COVID-19 infection or long-COVID features are associated with onset or worsening of MASLD and related metabolic conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria

1\. Age between 15 and 44 years. 2. Provision of informed consent to participate in the study. 3. Twin with a living co-twin. 4. Positive family history in first- and second-degree relatives of metabolic syndrome (MS), associated diseases, or the most common complications of the syndrome.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Exclusion Criteria

Permanent exclusion criteria:

1. Co-twin does not consent to participate in the study.
2. Inability to obtain medical history of biological family members.
3. Presence of advanced liver fibrosis, cirrhosis, or liver cancer.
4. Known liver genetic disorders, autoimmune hepatitis, celiac disease, hemochromatosis, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), cystic fibrosis, or Wilson's disease.
5. Current or chronic alcohol consumption \>20 g of ethanol/day in women and \>30 g/day in men.
6. Short bowel syndrome.
7. Cyanotic congenital heart defect.
8. Myasthenia.
9. Central nervous system degenerative diseases such as Alzheimer's disease, Parkinson's disease, or Huntington's disease.
10. Storage diseases involving the liver.
11. Active malignant neoplasm undergoing treatment (excluding non-melanoma skin cancers and melanoma treated non-pharmacologically).
12. Chronic kidney disease requiring renal replacement therapy.
13. Status post organ or tissue transplantation requiring immunosuppression.
14. Pituitary, hypothalamic, or adrenal hyperfunction/hypofunction requiring hormone supplementation.
15. Addiction to psychoactive substances or drugs.
16. Other severe and incurable diseases that, in the investigator's opinion, constitute a permanent contraindication for participation in the study.
17. Lack of cooperation by the volunteer during the visit to the Research Center. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Temporary exclusion criteria (after resolution, the volunteer may be enrolled):

1. Acute infection, low-grade fever or fever, or use of antibiotics at the time of recruitment or prior to the visit at the Research Center - inclusion possible after 6 weeks.
2. Any vaccination within the past 6 weeks.
3. Pregnancy and up to 6 months postpartum.
4. 3 months after the natural cessation of breastfeeding.
5. 3 months after surgery (does not apply to minor surgical procedures).
6. Untreated hyperthyroidism or hypothyroidism - inclusion possible 3 months after achieving euthyroidism.
7. Significant weight loss or gain in the past 3 months (\>10% of initial body weight) - inclusion possible 3 months after weight stabilization.
8. 6 months after discontinuation of temporary parenteral or enteral nutrition via feeding tube.
9. 12 months after bariatric surgery.
10. Systemic treatment with steroids, chemotherapy, immunosuppressive drugs, or biological therapy known to be hepatotoxic or potentially inducing abnormalities found in MS - inclusion possible at least 3 months after completing therapy.

Where it's running

• Uniwersytecki Szpital Kliniczny
  Poznan, Wielkopolska, Poland Recruiting

Study contacts

• Study coordinator: Piotr Eder, MD, Profesor
• Email: piotreder@ump.edu.pl
• Phone: +(48) 618691343

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fulvic acid supplements for metabolic syndrome

  This study tests whether 50 mg or 100 mg of fulvic acid daily for 12 weeks can help people with metabolic syndrome or prediabetes.

  Recruiting Arizona State University · Phoenix, Arizona · NCT07927283

• Asprosin and miRNA Profiles in Young Women with Metabolic Syndrome

  This study tests whether certain blood biomarkers, including asprosin and six microRNAs, differ between young women with metabolic syndrome and healthy peers.

  Recruiting University of Applied Sciences in Nowy Targ · Nowy Targ, Lesser Poland Voivodeship · NCT07917364

• Using Multimodal Ultrasound to Check Muscle Mass in Metabolic Disease Patients

  This study tests whether a multimodal ultrasound approach can accurately measure muscle mass in people with metabolic syndrome, obesity, sarcopenia, or type 2 diabetes.

  Recruiting Zhangzhou Municipal Hospital · Zhangzhou, Fujian · NCT07836088

• Low-Calorie Diet in adolescents with Familial Mediterranean Fever and metabolic syndrome

  A group of adolescents with both FMF and metabolic syndrome will try a low-calorie diet for 3 months to see if it helps manage metabolic symptoms.

  Recruiting Cairo University · Giza, Dokki · NCT07833007

• Exercise for Metabolic Syndrome and Fatty Liver in Adolescent Girls with Celiac Disease

  This study tests whether a 3-month walking program helps improve metabolic syndrome and fatty liver in adolescent females with celiac disease.

  Recruiting Cairo University · Giza, Dokki · NCT07832994

• Longevity Metrics AI/ML Development Study

  Researchers are testing AI models that score health screening tests and predict outcomes like life expectancy for adults, using ongoing follow-up data.

  Recruiting Longevity Metrics, Inc. · Boulder, Colorado · NCT07808619

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.